Halozyme Therapeutics (HALO) Share-based Compensation Growth (5y) (2015 - 2026)
Halozyme Therapeutics (HALO) Share-based Compensation Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Halozyme Therapeutics | 9.66 Bn | 9.34 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.99% |
| Dec 31, 2025 | 24.34% |
| Sep 30, 2025 | 48.87% |
| Jun 30, 2025 | -27.59% |
| Mar 31, 2025 | 46.36% |
| Dec 31, 2024 | 71.37% |
| Sep 30, 2024 | 29.59% |
| Jun 30, 2024 | -36.99% |
| Mar 31, 2024 | -44.72% |
| Dec 31, 2023 | 15.45% |
| Sep 30, 2023 | -47.10% |
| Jun 30, 2023 | -31.22% |
| Mar 31, 2023 | -45.36% |
| Dec 31, 2022 | 35.22% |
| Sep 30, 2022 | -37.29% |
| Jun 30, 2022 | -20.61% |
| Mar 31, 2022 | -8.30% |
| Dec 31, 2021 | -33.75% |
| Sep 30, 2021 | 18.23% |
| Jun 30, 2021 | -22.18% |